New low-dose chemo combo after transplant aims to stop leukemia relapse

NCT ID NCT06129734

First seen Apr 28, 2026 · Last updated Apr 30, 2026 · Updated 1 time

Summary

This study tests whether a milder chemotherapy combination (decitabine and venetoclax) given weekly after a bone marrow transplant can help prevent relapse in people with high-risk acute myeloid leukemia or related blood cancers. About 20 participants will receive the treatment for up to one year, alongside standard post-transplant care. The main goals are to see if the approach is safe and practical, and whether it improves survival without the cancer returning.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University Hospitals Seidman Cancer, Case Comprehensive Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.